Drugs / Trimetazidine
Trimetazidine
also known as
TMZ · trimetazidine hydrochloride · Dilatan · metacardia · NSC-759317 · Trimetazidina · Trimetazidine di-hcl · Trimetazidine dihydrochloride · +5 more
Trials 23 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03333499 Comparator | Nov 2017 → Dec 2018 | heart failure | Dalian University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06459193 Comparator | Jun 2024 → Jan 2025 | chemotherapy-induced neuropathy | Minia University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01696370 Comparator | Apr 2012 → Apr 2014 | hypertrophic cardiomyopathy | University College, London | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06656442 Comparator | Sep 2024 → Feb 2025 | ischemic stroke | Ain Shams University | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05633563 Comparator | Oct 2021 → Jun 2023 | mitochondrial disease, wild type ATTR amyloidosis | Steen Hvitfeldt Poulsen | Completed | No outcome recorded |
| Phase 4 | NCT04661709 Background | Mar 2021 → Mar 2023 | intermediate coronary syndrome | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03809273 Comparator | Aug 2019 → Dec 2020 | — | Shenyang Northern Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03072082 Background | Jun 2017 → Dec 2018 | coronary artery disorder | Jun Li | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04702906 Comparator | Feb → Jun 2021 | poisoning | Tanta University | Unknown | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimetazidine | “4. Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid” NCT04980716 ↗30 |
| Known as | Dilatan | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | metacardia | “trimetazidine hydrochloride "metacardia" ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)” NCT04702906 ↗ |
| Known as | NSC-759317 | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | TMZ | “Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI” NCT02107144 ↗2“This prospective study aimed to determine whether trimetazidine (TMZ) alters the pharmacodynamic (PD) effects of clopidogrel.” PMID 31292901 ↗ Jul 2019 “Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain.” NCT05633563 ↗ |
| Known as | Trimetazidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Trimetazidine di-hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Trimetazidine dihydrochloride | “The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride "metacardia" ® (20 mg three times daily produced by Pharco-Egypt) will...” NCT04702906 ↗ |
| Known as | Trimetazidine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | trimetazidine hydrochloride | “trimetazidine hydrochloride "metacardia" ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)” NCT04702906 ↗2“Trimetazidine hydrochloride may play an anti-tumor role by inhibiting fatty acid oxidation.” NCT03274427 ↗ |
| Known as | Trimethazidine dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Vastarel | “Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain.” NCT05633563 ↗ |
| Known as | Vastarel MR 35 mg | “When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours...” NCT03715582 ↗ |
| Known as | Vastarel mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Action | Inhibit | “free fatty acid inhibition with Trimetazidine” NCT00282360 ↗ |
| Modality | Small molecule | “Trimetazidine is a piperazine derivative.” NCT05147194 ↗ |
| Route | Oral | “oral therapy with trimetazidine” PMID 30725091 ↗ Mar 2019 |